Amelioration of intestinal fibrosis and treatment of Crohn's disease
US-9517241-B2 · Dec 13, 2016 · US
Vitamin D receptor/SMAD genomic circuit gates fibrotic response
US9872866B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9872866-B2 |
| Application number | US-201514921230-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 23, 2015 |
| Priority date | Apr 24, 2013 |
| Publication date | Jan 23, 2018 |
| Grant date | Jan 23, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis.
First claim
Opening claim text (preview).
We claim: 1. A method for treating pancreatic fibrosis in a subject, comprising: administering to the subject a therapeutically effective amount of a composition comprising a nanoparticle comprising retinyl palmitate on its surface, and calcipotriol, which is in or attached to the nanoparticle, thereby treating the pancreatic fibrosis in the subject. 2. The method of claim 1 , wherein the administering comprises orally administering the therapeutically effective amount of the composition into the subject. 3. The method of claim 1 , wherein the administering comprises intravenously, intrathecally, intramuscularly, intraperitoneally, intra-articularly, intratumorally, or subcutaneously administering a therapeutically effective amount of the composition into the subject. 4. The method of claim 1 , wherein the subject is a human subject. 5. The method of claim 1 , wherein the subject is a mammalian subject.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9872866B2 cover?
- The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis.
- Who is the assignee on this patent?
- Salk Inst For Biological Studi, Univ Sydney
- What technology area does this patent fall under?
- Primary CPC classification A61K31/592. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).